A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

NCT03255070 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Gastric Neoplasm
Solid Tumors

Interventions

DRUG: ARX788

Sponsor

Ambrx, Inc.